Literature DB >> 7115956

Myeloma protein kinetics following chemotherapy.

P McLaughlin, R Alexanian.   

Abstract

The effects of chemotherapy were evaluated in 43 multiple myeloma patients with high monoclonal globulin levels in both serum and urine. In responding patients, Bence Jones protein excretion declined more rapidly and markedly than the serum myeloma protein. Bence Jones protein excretion was reduced by 50% within 2 mo in responders, remained unchanged in nonresponders, and declined with a slow halving time of 2-7 mo in patients with partial disease control. Three patients with clinical resistance to treatment showed atypical protein changes and progressively more Bence Jones protein excretion relative to their serum monoclonal component. Serial measurements of Bence Jones protein excretion provided an early and reliable index of tumor mass change in patients with multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115956

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Thirty patients with primary plasma cell leukemia: a single center experience.

Authors:  Milica Colović; Gradimir Janković; Nada Suvajdzić; Natasa Milić; Vesna Dordević; Snezana Janković
Journal:  Med Oncol       Date:  2007-10-10       Impact factor: 3.064

2.  Appraisal of immunoglobulin free light chain as a marker of response.

Authors:  Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kimberly Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Journal:  Blood       Date:  2008-03-25       Impact factor: 22.113

3.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

Authors:  F Silvestris; A Romito; P Fanelli; A Vacca; F Dammacco
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.